SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Biotech / MedicalBreakthrough Company????? Endovasc ENDV


Previous 10 Next 10 
To: Abe Bleich who wrote ()3/6/2000 5:44:00 AM
From: Howard
   of 94
 
ENDV..... WOW!!!

I can't believe that after a run-up like we've seen last week that there is no mention of ENDV on SI. We ended the week up a few hundred percent and I as read it have a lot more to go.

The volume had not really increased much over the week and they will be presenting their data at a conference tomorrow (Tues March 7th) and at a Cardiology conference on March 13th. In my estimation, the run-up should see some profit taking from some long-term holders but then the run should continue to the end of the day in anticipation of tomorrow's meeting.

The two products that are in the pipeline could potentially eliminate the vast majority of cardiac bypasses performed in the US. The market is a 1-2 billion dollar market and ENDV themselves estimate 200-500 million in revenue by 2002 and 2005, respectively. One of their products is purported to decrease the restenosis (failure) rate of angioplasties to low single digits where it is 40% at present.

These two products sound great... we'll see what the company has to say tomorrow.... but come on... you gotta notice this puppy.

HJL MD

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Howard who wrote (84)3/6/2000 11:29:00 AM
From: Tom
   of 94
 
Seems to get more amazing as we speak. Can this all be about just the info to be released soon?

Share RecommendKeepReplyMark as Last Read


To: Howard who wrote (84)3/8/2000 11:58:00 PM
From: Cheryl Galt
   of 94
 
Howard, I'm sorry I missed this one. Congratulations on your nice profits.

ENDV has been invisible to me, since I mostly use Yahoo for delayed quotes and my watch-list portfolios
-- and ENDV.OB is not in Yahoo's database.
finance.yahoo.com

I sent a message to SI tech support, asking them to add a stock quote to the bottom of this thread's screen.

I'll also email Yahoo, tho I don't know if that will do any good. Responsiveness is not one of Yahoo's key virtues. ;-(

Endovasc sounds like an interesting company.
I'm particularly interested in restinosis developments, for personal reasons.

I've put Endovasc on my Do-DD list, and will be watching this thread.

Regards,
Cheryl

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Cheryl Galt who wrote (86)3/12/2000 12:07:00 PM
From: Constance Collard
   of 94
 
I've hung in with this one for well over a year and had almost forgotten about it. Sold half my position last week and will let the other half roll. Good luck to us all. CC

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Constance Collard who wrote (87)3/13/2000 6:30:00 PM
From: tiger-lily
   of 94
 
This ought to be great fun to trade ! ENDV... Nicotine cures cardiovascular heart disease. Just got worldwide rights from Stanford.. The Sharks are here & smelling blood & it isn't theirs LOL... I'm trading this one for fun & profit.

Share RecommendKeepReplyMark as Last Read


To: Abe Bleich who wrote ()4/21/2000 12:55:00 PM
From: YAH00Destroyer
   of 94
 
Funny how this board has no new posts recently. To get good info on ENDV, check out the raging bull bulletin board. There are many good posters on that board. (Of course, there are bad ones too.) A good one is Skivrmt. He is in the medical field and has a good understanding of the company.
YD

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: YAH00Destroyer who wrote (89)7/13/2000 2:43:40 PM
From: Dr David Summers
   of 94
 
From time to time I will answer questions relating to information already released by the Company. I am acting in the interest of the Company in protecting the shareholders from rumor, innuendo, and just flat lies posted by short-sellers, momentum traders, day traders and ax grinders and possibly real or potential competitors. As I have a equity in the Company and an interest its forward growth, I will post under my own name.

I will not however, respond to name-calling, denigration, slander, and the usual character assassination used by anonymous posters for self-aggrandizement.

If you are willing, I am willing to give truth a chance and enter into an honest non-privileged dialog about Endovasc and its technology

David P. Summers

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Dr David Summers who wrote (90)7/13/2000 2:52:35 PM
From: Brian Lempel
   of 94
 
Mr Summers,

It is fairly unorthodox for a CEO to appear in a public forum, but I welcome your input.

Specifically, there is discussion on a message board other than this one regarding your previous collaborative efforts with Bard. However, there has been no news coming out of this relationship, and many fear it has fallen apart. Could you discuss your current dealing with Bard, and where we might expect this to lead?

Also, and on a related topic, many are very interested in your progress in the biodegradable stent market. Would you be so kind as to give a brief description of your product, its maturity in testing, when we might expect it on the market, and most importantly, its targeted applications?

Thanks in advance,

Brian Lempel

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Brian Lempel who wrote (91)7/14/2000 6:25:48 PM
From: Dr David Summers
   of 94
 
Dear Mr. Lempel:

In reply to your questions:

The Bard relationship has not fallen apart, far from it. We are continually discussing various product development schemes, including peripheral stents and grafts. Bard is just slow, but eventually do make up their minds. I would expect their minds are about made up to go ahead with the next level of development. This could lead into an R&D partnership, equity investment, or various other potential.

We recently announced that we have received a patent for a biodegradable stent. The degradable stent differs from the metal stents as it is resorbed by the body after placement. As it is being resorbed, it can release various medicinal agents to the vessel wall which can range from anti-restenotics to anti-caner agents. At this time, our main efforts have been to perfect the Liprostin(tm) medicinal coatings on metal stents of "others" (which elute therapeutic levels of prostaglandin e-1) to inhibit smooth muscle cell (SMC) encroachment into the stent lumen, and to antagonize various plasma elements from stent adherence, ie, platelets, fibrin and thrombin, etc., to the stent body.

But as you suggested, the biodegradable stent market is the next window of opportunity and holds enormous market potential. We feel we have a significant edge in this development with our patented "field of use" of PGE-1 (which by-the-way is probably the potent SMC antimitogenic available) which patents its use in the field of post-angioplasty dysfunctions. I expect to have the biodegradable stent in animals next year. In the meantime, watch the take-off of "coated" metal stents which are ready for animal trials.

Thanks for the questions.

David P. Summers

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Dr David Summers who wrote (92)7/18/2000 12:37:47 AM
From: Brian Lempel
   of 94
 
Dr. Summers,

Please view your private messages by clicking on 'Inbox' at the top of this page.

Thanks,

Brian Lempel

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10